Related Experiment Video
Updated: Jun 29, 2025
07:20
Author Spotlight: Epigenetic Modifications and Metabolic Rewiring as Targets for Cancer Therapy
Published on: October 18, 2024
516
Role and potential therapeutic value of histone methyltransferases in drug resistance mechanisms in lung cancer
Linxiang Zhang1,2, Xueying Zhang1,2, Yan Shi1,2
1Key Laboratory of Clinical and Preclinical Research in Respiratory Disease, Molecular Diagnosis Center, The Department of Pulmonary Critical Care Medicine, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
Frontiers in Oncology
|March 25, 2024
Summary
Histone Methyltransferases (HMTs) drive lung cancer drug resistance through epigenetic changes. Targeting HMTs offers a promising strategy to overcome resistance and improve patient prognosis.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Lung cancer is a leading cause of cancer mortality globally.
- Drug resistance frequently occurs in lung cancer, leading to poor prognosis.
- Epigenetic mechanisms, particularly Histone Methyltransferases (HMTs), play a critical role in lung cancer drug resistance.
Purpose of the Study:
- To review the pivotal roles and molecular mechanisms of HMTs in lung cancer drug resistance.
- To explore HMT inhibitors as a therapeutic strategy for overcoming drug resistance.
- To provide insights for personalized treatment and drug development in lung cancer.
Main Methods:
- Comprehensive literature review of studies on HMTs and lung cancer drug resistance.
- Analysis of molecular pathways mediated by HMTs in drug tolerance.
- Examination of therapeutic strategies involving HMT inhibition.
Main Results:
- Abnormal HMT expression is linked to drug resistance in lung cancer.
- HMTs mediate drug tolerance via metabolic alterations, cancer stem cell gene upregulation, epithelial-mesenchymal transition, and enhanced migration.
- HMT inhibitors show potential in reversing drug resistance.
Conclusions:
- HMTs are key epigenetic regulators of drug resistance in lung cancer.
- Targeting HMTs represents a promising therapeutic avenue for improving lung cancer treatment outcomes.
- Further research into HMTs can support personalized medicine and novel drug development for lung cancer.
Related Concept Videos
02:32Histone Modification
13.3K
The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
13.3K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:25Spreading of Chromatin Modifications
8.3K
The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
Writers
The writer...
8.3K
01:46Epigenetic Regulation
31.1K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
31.1K
01:17Phase II Reactions: Methylation Reactions
186
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
186
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K